Foreword |
Preface |
Synthetic Routes for Venetoclax at Different Stages of Development / Yi-Yin Ku and Michael D. Wendt1: |
Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC / Robert Dugger and Bryan Li and Paul Richardson2: |
From Discovery to Market Readiness: The Research and Development of the ß-Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib / Rémy Angelaud and Steve Staben and Timothy Heffron and Andreas Schuster and Frédéric St-Jean3: |
Discovery and Development of the First Antibody-Antibiotic Conjugate Linker-Drug / Stefan G. Koenig and Thomas H. Pillow4: |
The Discovery of the Nav 1.7 Inhibitor GD C-0276 and Development of an Efficient Large-Scale Synthesis / Andreas Stumpf and Daniel Sutherlin and Christoph M. Dehnhardt and Rémy Angelaud5: |
Discovery and Development of AMG 333: A TRPM8 Antagonist for Migraine / Neil F. Langille and Daniel B. Home6: |
The Discovery and Chemical Development of PF-06273340: A Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor for Pain / David C. Blakemore and Thomas Brandt and Craig Knight and Sarah E. Skerratt7: |
Optimization of an Azaindazole Series of CCR1 Antagonists and Development of a Semicontinuous-Flow Synthesis / Christian Harcken and Joshuaine Grant and Hossein Razavi and Maurice A. Marsini and Frederic G. Buono and Jon C. Lorenz and Jonathan T. Reeves8: |
Discovery and Development of Non-Covalent, Reversible Bruton's Tyrosine Kinase Inhibitor Fenebrutinib(GDC-0853) / James J. Crawford and Haiming Zhang9: |
Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors / David W. Piotrowski and Emma L. McInturff10: |
Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection / Andrew J. Peat and Shiping Xie11: |
Editors' Biographies |
Indexes |
Author Index |
Subject Index |
Foreword |
Preface |
Synthetic Routes for Venetoclax at Different Stages of Development / Yi-Yin Ku and Michael D. Wendt1: |
Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC / Robert Dugger and Bryan Li and Paul Richardson2: |
From Discovery to Market Readiness: The Research and Development of the ß-Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib / Rémy Angelaud and Steve Staben and Timothy Heffron and Andreas Schuster and Frédéric St-Jean3: |
Discovery and Development of the First Antibody-Antibiotic Conjugate Linker-Drug / Stefan G. Koenig and Thomas H. Pillow4: |